McCoy to Leave J&J, Gorsky Prepares to Take Over - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

McCoy to Leave J&J, Gorsky Prepares to Take Over


ePT--the Electronic Newsletter of Pharmaceutical Technology

Johnson & Johnson announced this week that Sheri S. McCoy, vice-chairman of the Executive Committee, has resigned from the company. She was considered to be in line for the CEO position, being filled by Alex Gorsky.

McCoy, who joined J&J in 1982, is reportedly moving on to head Avon, a smaller company in comparison to J&J but with similar healthcare products in the cosmetic and skincare area.

“Sheri has made important contributions across Johnson & Johnson throughout her career. During these last several years, she was instrumental in helping to bring stronger strategic focus to our Pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges,”
 said J&J CEO and Chairman William C. Weldon, in a company statement.

J&J announced earlier this year that Gorsky would be succeeding Weldon, effective with the April 2012 annual shareholders’ meeting. Weldon served as Chairman and CEO since 2002. Gorsky is currently vice-chairman of the company’s Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy, and Government Affairs & Policy. Weldon will remain chairman of the company’s board of directors.


Comment from Reader J. Coupal, Lexington, KY:

"'..and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges.' '..[R]esolve some recent challenges' is the understatement of the year. A wide variety of seemingly unsolvable quality problems with McNeil Consumer products reflects performance of senior management responsible for quality oversight.It will take years for the public to regain enough confidence to buy and take those iconic products."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here